US20120027693A1 - Methods and compositions for preventing and relieving muscle cramps and for recovery from neuromuscular irritability and fatigue following exercise - Google Patents

Methods and compositions for preventing and relieving muscle cramps and for recovery from neuromuscular irritability and fatigue following exercise Download PDF

Info

Publication number
US20120027693A1
US20120027693A1 US13/191,941 US201113191941A US2012027693A1 US 20120027693 A1 US20120027693 A1 US 20120027693A1 US 201113191941 A US201113191941 A US 201113191941A US 2012027693 A1 US2012027693 A1 US 2012027693A1
Authority
US
United States
Prior art keywords
composition
acid
beverage
channel
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/191,941
Other languages
English (en)
Inventor
Bruce P. Bean
Donald MacKinnon
Roderick MacKinnon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cliff-Cartwright Corp
Salarius Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US13/191,941 priority Critical patent/US20120027693A1/en
Publication of US20120027693A1 publication Critical patent/US20120027693A1/en
Assigned to FLEX PHARMA, INC. reassignment FLEX PHARMA, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: MACKINNON, RODERICK, MACKINNON, DONALD, BEAN, BRUCE
Priority to US14/450,384 priority patent/US9937135B2/en
Priority to US15/241,986 priority patent/US10568853B2/en
Assigned to CLIFF-CARTWRIGHT CORPORATION reassignment CLIFF-CARTWRIGHT CORPORATION ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: SALARIUS PHARMACEUTICALS, INC.
Priority to US16/727,508 priority patent/US20200375925A1/en
Priority to US17/571,884 priority patent/US20220387539A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/67—Piperaceae (Pepper family), e.g. Jamaican pepper or kava
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9068—Zingiber, e.g. garden ginger
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • the invention relates to methods and compositions for preventing, treating or ameliorating muscle cramping and/or accelerating nerve-muscle recovery from exercise fatigue.
  • Muscle cramps the involuntary and forceful contraction of muscles, are often painful and can last for a prolonged period of time. Muscle contractions and cramping can be triggered by exercise and can also occur spontaneously (e.g., nocturnal or night cramps). The underlying physiological mechanism of muscle cramping is unknown. Recent understanding has led to the hypothesis that cramping results from excessive electrical firing of the neurons (motor neurons) that project from the spinal cord and trigger contraction of skeletal muscles (Schwellnus, Br J Sports Med. 43:401-8, 2009; Miller et al., Med Sci Sports Exerc. 42:953-61, 2010). Recovery from strenuous exercise can be associated with neuromuscular irritability, associated with neuromuscular fatigue, that may or may not be associated with the development of frank cramps. Few treatments and therapeutic regimens are available to alleviate this neuromuscular irritability.
  • compositions that include activators of TRP and ASIC channels may be useful to prevent, treat, or ameliorate muscle cramping and/or accelerate nerve-muscle recovery from, e.g., exercise fatigue. Further, these compositions can be useful in treating neuromuscular irritability that may or may not be associated with the development of frank cramps.
  • the present invention is directed to the prevention, treatment or amelioration of muscle cramps and/or accelerating nerve-muscle recovery from exercise fatigue using a composition with an activator of TRPV1 channels, an activator of TRPA1 channels, and/or an activator of ASIC channels.
  • the invention features a method for treating muscle cramps in a subject in need thereof (e.g., a human), the method including the step of administering to the subject a composition that includes an effective amount of one or more TRPV1 channel activators, TRPA1 channel activators, or ASIC channel activators, or any combination thereof.
  • the invention also features a method for treating musculoskeletal irritability in a subject in need thereof.
  • the method includes administering to the subject a composition that includes an effective amount of one or more TRPV1 channel activators, TRPA1 channel activators, or ASIC channel activators, or any combination thereof.
  • the invention features a method for improving muscle recovery (e.g., muscle recovery following exercise) in a subject in need thereof, where the method includes administering to the subject a composition that includes an effective amount of one or more TRPV1 channel activators, TRPA1 channel activators, or ASIC channel activators, or any combination thereof.
  • the composition can be, e.g., an oral formulation (e.g., a liquid, beverage, gel, semi-solid, frozen liquid, lozenge, hard candy, dissolving strip, or spray).
  • an oral formulation e.g., a liquid, beverage, gel, semi-solid, frozen liquid, lozenge, hard candy, dissolving strip, or spray.
  • the composition is administered to the subject prior to exercise, during exercise, or following exercise (e.g., within 0-120 minutes prior to exercise, or within 0-360 minutes, 0-15 minutes, or 2-6 hours following exercise.
  • Muscle cramps that can be treated or prevented using the methods and compositions described herein include, e.g., muscle cramps resulting from exercise, nocturnal cramps, and menstrual cramps.
  • the composition includes an effective amount of two or three different TRP channel activators independently selected from:
  • each channel activator independently, includes between 0.001% to 1% weight percent of a composition that is a solid, semi-solid, gel, or chewing gum, or 0.001 to 1% (v/v) of a composition that is a liquid, beverage, or spray.
  • the composition is any of the compositions described herein.
  • the invention also features a composition formulated for oral ingestion by a subject.
  • the composition includes an effective amount of one or more channel activators (e.g., one or more substantially pure channel activators) selected from TRPV1 channel activators, TRPA1 channel activators, and ASIC channel activators.
  • the composition is a liquid, beverage, gel, semi-solid, frozen liquid, lozenge, hard candy, dissolving strip, or spray.
  • the channel activator is capable of activation of a channel in a gastroesophogeal neuron when administered to a subject
  • the channel activators can be substantially pure or not substantially pure (e.g., part of a crude extract).
  • the channel activators are capable of activation of a channel in a gastroesophogeal neuron when administered to a subject.
  • the TRPV1 channel activator can be is a capsaicinoid (e.g., capsaicin).
  • the composition contains capsaicin but is substantially free of dihydrocapsaicin.
  • the TRPV1 channel activator can also be, e.g., oleoylethanolamide, N-oleoyldopamine, 3-methyl-N-oleoyldopamine, oleamide, capsiate, a 1-monoacylglycerol having C18 and C20 unsaturated and C8-C12 saturated fatty acid, a 2-monoacylglycerol having C18 and C20 unsaturated fatty acids, miogadial, miogatrial, polygodial, a terpenoid with an alpha,beta-unsaturated 1,4-dialdehyde moiety, sanshool, evodiamine, acesulfame-K, cyclamate, CuSO 4 , ZnSO 4 , FeSO 4 , arvanil, anandamide, N-arachidonoyl-dopamine, flufenamic acid dopamide, a dopamine amide of fenamic acid, 4-hydroxy
  • Suitable TRPA1 channel activators include, e.g., allyl isothiocyanate, gingerols, cinnamaldehyde, acrolein, farnesyl thiosalicylic acid, ⁇ 9 -tetrahydrocannabinol, eugenol, shogaols, nicotine, nicotine derivatives or analogs, methyl salicylate, cinnamaldehyde, allicin, diallyl sulfide, diallyl disulfide, diallyl trisulfide, sanshools, and farnesyl thioacetic acid.
  • Each channel activator can be present, e.g., between 0.001% to 1% (w/w) or 0.001 to 1% (v/v) of a composition.
  • the composition includes no more than one TRPV1 channel activator, TRPA1 channel activator, or ASIC channel activator.
  • the composition includes a TRPV1 channel activator and a TRPA1 channel activator (e.g., a substantially pure TRPA1 channel activator and/or a substantially pure TRPV1 channel activator).
  • the composition includes no more than one TRPV1 channel activator and no more than one TRPA1 channel activator.
  • the composition includes a second TRPV1 channel activator and/or a second TRPA1 channel activator.
  • the composition includes can include an effective amount of an ASIC channel activator (e.g., a substantially pure ASIC channel activator).
  • the ASIC channel activator e.g., a substantially pure ASIC channel activator
  • the ASIC channel activator is capable of activation of an ASIC channel in a gastroesophogeal neuron when administered to a subject.
  • the ASIC channel activator is an acidulant that is acetic acid.
  • the composition is a liquid or beverage that has an acetic acid concentration ranging from 0 M to 0.1 M (e.g., from 0 M to 0.001 M).
  • the ASIC channel activator is an acidulant selected from phosphoric acid, citric acid, malic acid, succinic acid, tartaric acid, fumaric acid, and ascorbic acid.
  • the invention also features a composition that includes an effective amount of two or three different TRP channel activators independently selected from capsaicin or another capsaicinoid; cinnamaldehyde or cinnamon oil; and gingerols, where the composition is an oral formulation that is a liquid, beverage, gel, solid, semi-solid, chewing gum, or spray.
  • the composition includes an effective amount of two or three different TRP channel activators independently selected from: capsicum; cinnamon volatile oil; and ginger oleoresin.
  • the composition can include each of the components.
  • the capsaicinoid is present in 0.001% to 1% (w/w) or 0.001% to 1% (v/v); and/or the cinnamaldehyde or cinnamon oil is present in 0.001% to 10% (w/w) or 0.001% to 10% (v/v); and/or the gingerols are present in 0.001% to 10% (w/w) or 0.001% to 10% (v/v).
  • the composition is a beverage that optionally includes a sweetener.
  • a composition of the invention can also include an acidulant selected from acetic acid, phosphoric acid, citric acid, malic acid, succinic acid, tartaric acid, fumaric acid, acetic acid, and ascorbic acid.
  • an acidulant selected from acetic acid, phosphoric acid, citric acid, malic acid, succinic acid, tartaric acid, fumaric acid, acetic acid, and ascorbic acid.
  • the composition can also include a potassium salt at a concentration of between about 0.02% and about 7% by weight based on total volume of the liquid, beverage, or gel.
  • the composition can be a liquid, beverage, or gel that also includes a viscosity modifier, such as collagen, gellan gum, carbohydrate gel-forming polymers, carob bean gum, locust bean gum, carrageenan, alginic acid, sodium alginate, potassium alginate, ammonium alginate, calcium alginate, agar, guar gum, xanthan gum, carboxymethyl cellulose, clear starch, pectin, gelatin, arrowroot, cornstarch, katakuri starch, potato starch, sago, tapioca, furcellaran, or sodium pyrophosphate.
  • the composition has a viscosity between about 1000 and about 10000 cP (e.g., 1000, 2000, 3000, 4000, 5000, 6000, 7000, 8000, 9000, or 10000 cP).
  • the composition also includes one or more of electrolytes, sweeteners, flavoring agents, vitamins, minerals, amino acids, or preservatives.
  • the composition is a beverage or gel that is made by reconstituting a dry powder with an aqueous fluid (e.g., water).
  • aqueous fluid e.g., water
  • the composition is a packaged beverage.
  • the packaged beverage is provided in a unit that contains between 10-1000 mL (e.g., between 10-500 mL) of the beverage.
  • the composition is a gel.
  • the composition is a packaged gel.
  • the packaged gel is provided in a unit that contains between 5-100 grams (e.g., between 30-40 grams) of the gel.
  • the composition has a pH that is greater than about 2.5 (e.g., the pH of the composition is greater than about 2.5, 2.6, 2.7, 2.8, 2.9, 3.0, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4.0, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5.0, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6.0, 6.1, 6.2, 6.3, 6.4, or 6.5).
  • the composition can have a pH of about 4 to about 9, about 5 to about 9, or 6.5 to about 7.5.
  • the composition is a liquid or beverage that does not include acetic acid or a salt thereof, or that has an acetic acid concentration ranging from 0 M to 0.1 M, 0 M to 0.001 M, is substantially 0 M.
  • the TRPV1 channel activator is a proton concentration of 10 ⁇ 7 M to 10 ⁇ 2 M (pH 2-pH 7), e.g. produced by inclusion of acidulants such as acetic acid, phosphoric acid, citric acid, malic acid, succinic acid, tartaric acid, fumaric acid, and ascorbic acid.
  • acidulants such as acetic acid, phosphoric acid, citric acid, malic acid, succinic acid, tartaric acid, fumaric acid, and ascorbic acid.
  • the composition includes vinegar (e.g., apple cider vinegar)
  • the composition includes no more than one of garlic (e.g., garlic extracts) or ginger (e.g., ginger extracts).
  • the composition includes garlic (e.g., garlic extracts)
  • the composition includes no more than one of vinegar (e.g., apple cider vinegar) or ginger (e.g., ginger extracts).
  • the composition includes ginger (e.g., ginger extracts)
  • the composition includes no more than one of garlic (e.g., garlic extracts) or vinegar (e.g., apple cider vinegar).
  • compositions described herein can be used in any of the methods described herein (e.g., to treat muscle cramps such as nocturnal cramps or menstrual cramps, or muscle cramps resulting from exercise, to treat musculoskeletal irritability, or to improve muscle recovery).
  • the compositions used in the methods can include substantially pure channel activators.
  • the TRP channel (e.g., a TRPV1 or TRPA1 activator) activator and/or the ASIC channel activator is not substantially pure.
  • a composition can include a mixture of capsaicinoids (e.g., as capsicum or between 0.0001-0.01 mgs/mL of total capsaicinoids).
  • the channel activators are provided as extracts suitable for human consumption.
  • the invention features a method of preparing any of the compositions described herein for treating or ameliorating muscle cramps in a subject in need thereof, or for treating musculoskeletal irritability in a subject in need thereof, the method including the use of TRP or ASIC channel activator compounds that are substantially pure with an excipient to provide a composition that is a liquid, beverage, gel, solid, semi-solid, chewing gum, or spray.
  • ASIC channel is meant an acid sensing ion channel that is opened by low pH and can excite certain neurons or muscle fibers or other cells.
  • acidulant is meant an acidic compound (e.g., citric acid) used to lower the pH of a composition, e.g., the pH can be lowered in the range of 2.5-6.5 (e.g., pH of 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, or 6.5).
  • acidic compound e.g., citric acid
  • the pH can be lowered in the range of 2.5-6.5 (e.g., pH of 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, or 6.5).
  • activator By “activator,” “compound that activates,” or “agonist” is meant a molecule that stimulates a biological response.
  • administering and “administration” is meant a mode of delivery.
  • a daily dosage can be divided into one, two, three or more doses in a suitable form to be administered one, two, three or more times throughout a time period.
  • compositions and solutions are administered orally.
  • beverage is meant a composition that is not in solid or gas form, such as a liquid or semi-liquid that is designed to enter into the mouth of a subject and be orally consumed or ingested.
  • a beverage may be in a ready-to-drink liquid form (e.g., may be consumed without modification) or in a liquid, solid, or concentrated form, which can be transformed into a ready-to-drink liquid form with an addition of another liquid (e.g., water).
  • a ready-to-drink liquid form e.g., may be consumed without modification
  • a liquid, solid, or concentrated form which can be transformed into a ready-to-drink liquid form with an addition of another liquid (e.g., water).
  • composition is used to describe a formulation that includes an activator of TRPV1 channels, and/or an activator of TRPA1 channels, and/or an activator of ASIC channels, the term refers to a comestible formulation that is suitable for oral ingestion by the subject (e.g., the human subject).
  • compositions that include an activator of TRPV1, TRPA1, and ASIC channels include sprays (e.g., aerosols), powders, chewing gum, ingestible solids, gels, aqueous beverages, dry powder (e.g., a powder that can be directly consumed or that can be reconstituted with liquid to provide a beverage as defined herein), nutritional bars, lozenges, tablets, capsules, wafers, pastes, and the like. Other compositions are described herein.
  • an “effective amount” of a compound as used herein is that amount sufficient to effect beneficial or desired results, such as the effective treatment of muscle cramps or musculoskeletal irritability or the improvement of muscle recovery following exercise, and, as such, an “effective amount” depends upon the context in which it is being applied.
  • an effective amount of an agent is, for example, an amount sufficient to achieve an increase in TRPV1, TRPA1, or ASIC activity as compared to the response obtained without administration of the agent.
  • the effective amount of active compound(s) used to practice the present invention can also be varied based on, for example, the age, and body weight, of the subject or the nature of the exercise.
  • compositions can also include one more excipients that are not activators of TRPV1, TRPA1, and ASIC channels and that are non-toxic and non-inflammatory in a subject (e.g., in a human subject).
  • excipient(s) can provide desirable or improved physical and/or chemical properties such as stability, flow, viscosity, rate of disintegration, taste, delivery, etc.
  • Exemplary, non-limiting excipients that can be selected from: a disintegrant (e.g., carmellose, starch, crystalline cellulose, low-substituted hydroxypropyl cellulose, and the like), a binder (e.g., gum acacia, carmellose, gelatin, crystalline cellulose, simple syrup, honey, hydroxypropyl cellulose, povidone, methylcellulose, and the like), a surfactant (e.g., polyoxyl 40 stearate, polysorbate 80, polyoxyethylene hydrogenated castor oil, and the like), an emulsifier (e.g., polyoxyl 40 stearate, sorbitan sesquioleate, polysorbate 80, sodium lauryl sulfate, lauromacrogol, gum arabic, cholesterol, stearic acid, povidone, glyceryl monostearate, and the like), a plasticizer (e.g., glycerin, propylene glycol,
  • ingestible solid is meant a solid formulation that can be ingested by a subject (e.g., a human) without toxic effects.
  • muscle cramp is meant a spontaneous contraction of one or more muscles.
  • a muscle cramp may be associated with strenuous exercise or fatigue or may occur during rest (e.g., a nocturnal cramp). Menstrual cramps are also muscle cramps
  • muscle recovery or “muscle recovery” is meant the recovery from spontaneous muscle contractions and fatigue following exercise that may or may not be associated with the development of frank cramps.
  • spontaneous muscle contractions e.g. associated with muscle fatigue
  • frank cramps spontaneous muscle contractions
  • preventing or “reducing the likelihood of” is meant reducing the severity, the frequency, and/or the duration of a condition or disorder (e.g., muscle cramping) or the symptoms thereof.
  • reducing the likelihood of or preventing muscle cramping is synonymous with prophylaxis of muscle cramping.
  • subject is meant a mammal, including, but not limited to, a human or non-human mammal, such as a bovine, equine, canine, ovine, or feline.
  • the term “substantially pure” refers to a composition that includes a channel activator in which the composition is free of organic and/or inorganic species that do not activate the TRPA1, TRPV1, and/or ASIC channels, and where 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99%, or 99.5% (w/w) of the composition is a particular channel activator compound.
  • Substantially pure compositions can be prepared and analyzed using standard methods known in the art (e.g., chromatographic separation, extractions, and the like).
  • Substantially pure compositions can include isomeric impurities (e.g., geometric isomers) and/or salts or solvates of a channel activator.
  • treating or “ameliorating” is meant administering a composition for therapeutic purposes or administering treatment to a subject already suffering from a disorder to improve the subject's condition.
  • treating a condition or disorder or “ameliorating a condition or disorder” is meant that the condition or disorder (e.g., muscle cramping) and the symptoms associated with the condition or disorder are, e.g., alleviated, reduced, cured, or placed in a state of remission.
  • amelioration or degree of treatment is at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 99%, or 100%, as measured by any standard technique.
  • TRPV1 transient receptor potential cation channel, subfamily V, member 1
  • TRPV1 channel activators include, e.g., capsaicinoids and capsaicinoid analogs or derivatives and certain endocannabinoids.
  • transient receptor potential cation channel, subfamily A, member 1 or “TRPA1” is meant a cation channel that is a member of the transient receptor potential channel family.
  • TRPA1 channel activators include, e.g., allyl isothiocyanate, cinnamaldehyde, farnesyl thiosalicylic acid, nicotine and its structural analogues, formalin, hydrogen peroxide, 4-hydroxynonenal, and acrolein.
  • viscosity is meant a measurement of a fluid's internal resistance to flow (e.g., “thickness”). Viscosity is generally expressed in centipoise (cP) or pascal-seconds.
  • FIG. 1 shows graphs from 6 sensory neurons isolated from the trigeminal ganglia of rats that illustrate their activation by the capsicum, cinnamon, and ginger extracts that were used in the human experiments. These data show that each agent is capable of acting alone to activate some neurons but also that a combination of agents can produce stronger activation of a larger fraction of neurons. Further, the bottom two records suggest that there can be strongly synergistic activation of neurons by the capsicum extract and the ginger extract when applied in combination.
  • FIG. 2 shows the effect of the TRP-Stim beverage on cramping of the flexor hallucis brevis (FHB) of Subject A.
  • cramping was reliably induced by stimulating the muscle using an electrical muscle stimulator.
  • TRPV1 agonists capsaicin and capsaicinoids
  • TRPA1 agonist cinnamaldehyde
  • TRPA1 and TRPV1 agonists cramping was very brief after 11 minutes and essentially absent at tests at 20 minutes and 21 ⁇ 2 hours after ingestion.
  • FIG. 3 shows the effect of the TRP-Stim beverage on cramping of the FHB of a second subject after cramping was induced.
  • stimulation at 10 Hz or 12 Hz produced essentially no cramping, and increasing the frequency of stimulation to 14 Hz also did not induce cramping. The dramatic reduction in cramping was still present 4 hours later in this subject.
  • FIG. 4 shows the effect of the TRP-Stim beverage on cramping of the FHB of a third subject tested over longer times. Under control conditions, a cramp lasting 58 seconds was induced. After ingestion of the TRP-Stim beverage, the duration of the cramp was reduced to 27 seconds after 8 minutes, to 8 seconds after 15 minutes, and cramping was abolished after 20 minutes and in a test after 2 hours. In tests 11 hours after ingestion, reliable cramping had returned. After the subject again drank 50 mL of the TRP-Stim beverage, cramping was completely abolished in tests beginning after 10 minutes.
  • FIG. 5 shows the effect of the TRP-Stim beverage on cramping of the FHB of a fourth subject.
  • This subject had engaged in strenuous exercise (triathlon) four hours earlier and was experiencing muscle twitchiness.
  • This subject had an unusually low frequency threshold (8 Hz) for induction of cramping in the FHB muscle, and the resulting cramps were unusually long (172 seconds after 8 Hz stimulation and 222 seconds after 10 Hz stimulation).
  • Cramping was completely gone in tests starting 13 minutes after ingestion of the TRP-Stim beverage, even when increasing the stimulation frequency to 12 Hz. Cramping was still abolished 3 hours later. After 4 hours, cramping returned, but with an increased frequency threshold (10 Hz). After the subject again drank 50 mL of the TRP-Stim beverage, cramping was again completely abolished.
  • FIG. 6 is a graph showing the effect of the TRP-Stim beverage on cramping of the gastrocnemius (calf) muscle of a fifth subject.
  • the muscle was stimulated, and after cessation of stimulation, the muscle went into a prolonged cramp lasting 59 seconds. In a test 3 minutes after ingestion of 50 mL of TRP-Stim, cramping was abolished.
  • FIG. 7 shows the effect of the TRP-Stim beverage on cramping of the gastrocnemius (calf) muscle of a sixth subject.
  • the muscle was stimulated, and after cessation of stimulation, the muscle went into a prolonged cramp lasting 96 seconds.
  • cramping was abolished.
  • Cramping was still abolished in a test conducted 40 minutes later.
  • FIG. 8 is a graph showing the effect of the TRP-Stim beverage on cramping of an FHB muscle in a seventh subject who experienced spontaneous cramping induced by pointing her toe. Ten minutes after the subject ingested 50 mL of the TRP-Stim beverage, cramping was abolished.
  • compositions of the present invention are directed to the treatment or amelioration of muscle cramps using a composition that includes one or more TRPV1 channel activators and/or TRPA1 channel activators and/or ASIC channel activators.
  • TRPV1, TRPA1, and ASIC channels are known to be present in gastroesophageal polymodal sensory neurons that mediate transmission of a variety of noxious stimuli, including mechanical, chemical, and thermal stimul (Beilefeldt et al., Am J Physiol Gastrointest Liver Physiol 294: G130-G138, 2008; Yu et al., Am J Physiol Gastrointest Liver Physiol 297: G34-G42, 2009).
  • These primary sensory neurons project to the spinal cord and brain stem, where they release glutamate and a variety of neuropeptides (e.g., calcitonin gene-related peptide (CGRP) and substance P).
  • CGRP calcitonin gene-related peptide
  • These transmitters act broadly on other types of neurons within the spinal cord and brain stem circuitry, including neurons that release GABA, glycine, and serotonin in the spinal cord, which can in turn inhibit firing of motor neurons.
  • Activity of inhibitory neurons in the spinal cord and brain stem may thus be triggered by stimulation of molecular targets (e.g., TRPV1 and TRPA1 and ASIC channels) present in primary sensory nerve endings in the mouth, esophagus and/or stomach, resulting in inhibition of the motor neurons whose excessive firing is responsible for muscle cramping.
  • molecular targets e.g., TRPV1 and TRPA1 and ASIC channels
  • some cramps can be prevented by local nerve block and appear to result from impairment of function of GABAergic interneurons in the spinal cord (Obi et al., Muscle and Nerve 6:1228-1231, 1993).
  • compositions described herein are comestible formulations suitable for oral consumption by a subject (e.g., by a human) and include one or more activators of TRPV1, TRPA1, and/or ASIC channels as well as one or more optional excipients as described herein.
  • exemplary, non-limiting compositions include those that are solids (e.g., chews or chewing gums), liquids (e.g., beverages), and gels.
  • TRPV1 Compounds that activate TRPV1 that may be used in the compositions of the present invention include, for example, capsaicin, capsaicin analogs and derivatives (e.g., capsaicinoids), and any other compound that activates TRPV1, examples of which are described herein.
  • Modulators of TRPV1 activity are known in the art (see, e.g., Harteneck et al., “Synthetic modulators of TRP channel activity,” Adv Exp Med Biol. 704:87-106, 2011, and other references described herein).
  • the TRPV1 channel activator is a capsaicinoid (e.g., capsaicin (8-methyl-N-vanillyl-trans-6-nonenamide)).
  • capsaicin 8-methyl-N-vanillyl-trans-6-nonenamide
  • Exemplary capsaicinoids are provided in Table 1.
  • Suitable capsaicinoids and capsaicinoid analogs and derivatives for use in the compositions and methods of the present invention include naturally occurring and synthetic capsaicin derivatives and analogs including, e.g., vanilloids (e.g., N-vanillyl-alkanedienamides, N-vanillyl-alkanedienyls, and N-vanillyl-cis-monounsaturated alkenamides), capsiate, dihydrocapsiate, nordihydrocapsiate and other capsinoids, capsiconiate, dihydrocapsiconiate and other coniferyl esters, capsiconinoid, resiniferatoxin, tinyatoxin, civamide, N-phenylmethylalkenamide capsaicin derivatives, olvanil, N-[(4-(2-aminoethoxy)-3-methoxyphenyl)methyl]-9Z-octa-decanamide, N-oleyl-homovanill
  • TRPV1 channel activators include oleoylethanolamide, N-oleoyldopamine, 3-methyl-N-oleoyldopamine, oleamide, capsiate, 1-monoacylglycerols having C18 and C20 unsaturated and C8-C12 saturated fatty acid, 2-monoacylglycerols having C18 and C20 unsaturated fatty acids, miogadial, miogatrial, polygodial, and other terpenoids with an alpha,beta-unsaturated 1,4-dialdehyde moiety, sanshools, evodiamine, acesulfame-K, cyclamate, sulfates (e.g., CuSO 4 , ZnSO 4 , and FeSO 4 ), arvanil, anandamide, N-arachidonoyl-dopamine, flufenamic acid dopamide and other dopamine amides of fenamic acids, 4-
  • TRPV1 channel activator may be an analog or derivative of any of the TRPV1 channel activators described herein.
  • TRPV1 channel activators are described, for example, in U.S. Pat. Nos. 7,632,519; 7,446,226; 7,429,673; 7,407,950; 6,022,718; 5,962,532; 5,762,963; 5,403,868; 5,290,816; 5,221,692; 4,812,446; 4,599,342; 4,564,633; 4,544,669; 4,544,668; 4,532,139; 4,493,848; 4,424,205; 4,313,958; in U.S. Patent Application Publication Nos. 2007/0293703; 2007/0167524; 2006/0240097; and 2005/0085652; and in WO 00/50387, each of which is incorporated by reference.
  • the TRPV1 channel activator may be an acidulant (e.g., acetic acid, phosphoric acid, citric acid, malic acid, succinic acid, tartaric acid, fumaric acid, or ascorbic acid) maintaining a low pH in the range of 2.5-6.5 (e.g., pH of 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, or 6.5).
  • an acidulant e.g., acetic acid, phosphoric acid, citric acid, malic acid, succinic acid, tartaric acid, fumaric acid, or ascorbic acid
  • 2.5-6.5 e.g., pH of 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, or 6.5.
  • TRPV1 channel activators for use in the compositions and methods described herein can be identified using standard methodology, as described, for example, in U.S. Patent Application Publication No. 2003/0104085, which is hereby incorporated by reference.
  • Exemplary assays for identification of TRPV1 channel activators include, without limitation, receptor binding assays; functional assessments of stimulation of calcium influx or membrane potential in cells expressing the TRPV1 receptor; assays for the ability to induce cell death in such cells (e.g., selective ablation of C-fiber neurons); and other assays known in the art.
  • a TRPV1 channel activator may be present in a composition of the invention at a concentration range of about 0.01% to 10% by weight by weight based on the total volume of the composition (e.g., 0.01, 0.1, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10%), though a TRPV1 channel activator may be present in lower or higher concentrations.
  • TRPA1 channels are activated by naturally occurring substances including, e.g., mustard oil, isothiocyanate compounds (e.g., allyl isothiocyanate), acrolein, farnesyl thiosalicylic acid, ⁇ 9 -tetrahydrocannabinol (THC), eugenol, ginger, gingerol, gingerols, shogaols, nicotine, nicotine derivatives and analogs, methyl salicylate, cinnamaldehyde, cinnamon oil, wintergreen oil, clove oil, allicin, diallyl sulfide, diallyl disulfide, diallyl trisulfide, sanshools, farnesyl thiosalicylic acid, and farnesyl thioacetic acid.
  • mustard oil isothiocyanate compounds (e.g., allyl isothiocyanate), acrolein, farnesyl thiosalicylic acid, ⁇
  • the TRPA1 channel activator may also be an analog or derivative of any of the TRPA1 channel activators described herein, and additional TRPA1 channel activators are identified in WO 2009/071631, hereby incorporated by reference. Still other modulators of TRPA1 are described in, e.g., Harteneck et al., “Synthetic modulators of TRP channel activity,” Adv Exp Med Biol. 704:87-106, 2011; Viana et al. “TRPA1 modulators in preclinical development,” Expert Opin. Ther. Pat. 19(12):1787-99, 2009).
  • TRPA1 channel activators are known in the art and are described, for example, in U.S. Pat. No. 7,674,594.
  • a TRPA1 channel activator may be present in a composition of the invention at a concentration range of about 0.01% to 10% by weight by weight based on the total volume of the composition (e.g., 0.01, 0.1, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10%), though a TRPA1 channel activator may be present in lower or higher concentrations.
  • ASIC channels are activated by low pH.
  • the pH of a composition of the present invention that includes an ASIC channel activator may be in the range of 2.5-6.5 (e.g., pH of 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, or 6.5).
  • the pH may be adjusted within this range by any means acceptable for compositions that are intended to be ingested by a subject.
  • Exemplary acidulants are acetic acid, phosphoric acid, citric acid, malic acid, succinic acid, tartaric acid, fumaric acid, and ascorbic acid.
  • the acidulant may be present in a composition of the invention at a concentration range of about 0.01% to 10% by weight based on the total volume of the composition (e.g., 0.01, 0.1, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10%), though the acidulant may be present in lower or higher concentrations.
  • composition of the present invention may additionally include, for example, electrolytes (e.g., potassium salt or other salts), sweeteners, flavoring and coloring agents, vitamins, minerals, preservatives, and antioxidants.
  • electrolytes e.g., potassium salt or other salts
  • sweeteners e.g., potassium salt or other salts
  • flavoring and coloring agents e.g., vitamins, minerals, preservatives, and antioxidants.
  • Viscosity is the ratio of shear stress to shear rate, expressed as dynes-second/cm 2 , or poise.
  • a centipoise (cP) is one one-hundredth of a poise.
  • the composition of the present invention may have a viscosity greater than water (i.e., about 1.0 cP at 20° C.), e.g., about 100, 200, 300, 400, 500, 1000, 1500, 2000, 2500, 3000, 3500, 4000, 4500, 5000, 6000, 7000, 8000, 9000 cP or more. If a consistency of corn syrup is desired, viscosities in the range of about 2500 cP are suitable. If a consistency of a soft gel or honey is desired, viscosities in the range of about 10000 cP to about 15000 cP are suitable. For pudding-like products, viscosities in the range of about 30000 cP to about 38000 cP are desirable. Viscosity of the compositions of the present invention may be measured with, e.g., a rheometer or viscometer, though additional methods of measuring viscosity are known in the art.
  • Viscosity modifiers may be added to compositions of the present invention.
  • Such viscosity modifiers include, for example, collagen, gellan gum, carbohydrate gel-forming polymers, carob bean gum, locust bean gum, carrageenan, alginates (e.g., alginic acid, sodium alginate, potassium alginate, ammonium alginate, and calcium alginate), agar, guar gum, xanthan gum, carboxymethyl cellulose, clear starch, pectin, gelatin, arrowroot, cornstarch, katakuri starch, potato starch, sago, tapioca, furcellaran, and sodium pyrophosphate.
  • alginates e.g., alginic acid, sodium alginate, potassium alginate, ammonium alginate, and calcium alginate
  • agar guar gum
  • xanthan gum carboxymethyl cellulose
  • clear starch pectin
  • gelatin arrowroot
  • a viscosity modifier may be present in the composition in an amount of from about 0.01% to 10% by weight based on the total volume of the composition (e.g., 0.01, 0.1, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10%), though the viscosity modifier may be present in lower or higher concentrations.
  • Exemplary electrolytes include potassium salts, chloride salts, bromide salts, sodium salts, magnesium salts, calcium salts, citrate salts, acetate salts, phosphate salts, salicylates, bicarbonate salts, lactate salts, sulphate salts, tartrate salts, benzoate salts, selenite salts, molybdate salts, iodide salts, oxides, and combinations thereof.
  • An electrolyte may be present in a composition of the invention at a concentration range of about 0.01% to 10% by weight based on the total volume of the composition (e.g., 0.01, 0.02, 0.03, 0.04, 0.05, 0.1, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10%), though an electrolyte may be present in lower or higher concentrations.
  • the compositions of the present invention include high concentrations of potassium (e.g., potassium chloride).
  • concentration of potassium in the composition may be, e.g., 0.01, 0.02, 0.03, 0.04, 0.05, 0.1, 0.5, 1, 2, 3, 4, 5, 6, or 7% or more by weight based on the total volume of the composition.
  • the compositions of the present invention include high concentrations of magnesium (e.g., magnesium chloride).
  • concentration of magnesium in the composition may be, e.g., 0.01, 0.02, 0.03, 0.04, 0.05, 0.1, 0.5, 1, 2, 3, 4, 5, 6, or 7% or more by weight based on the total volume of the composition.
  • Sweeteners may be included in the compositions of the invention.
  • Exemplary sweeteners include high fructose corn syrup, mannose, maltose, glucose polymers, sucrose (e.g., cane sugar or beet sugar), glucose, dextrose, lactose, galactose, fructose, polysaccharides (e.g., malodextrins), rice syrup, honey, and natural fruit juices (e.g., orange juice, papaya juice, pineapple juice, apple juice, grape juice, apricot juice, pear juice, tomato juice, agave nectar, or cranberry juice). Additionally, non- or low-caloric sweeteners can be used in the compositions of the invention.
  • non-caloric or low-caloric sweeteners include, but are not limited to, saccharin, cyclamates, acetosulfam, sorbitol, sucralose, xylitol, erythritol, Stevia extract, L-aspartyl-L-phenyl-alanine ester (e.g., aspartame), L-aspartyl-D-alanine alkyl amides, L-aspartyl-L-1-hydroxymethylalkaneamide, and L-aspartyl-1-hydroxyethylalkaneamide.
  • saccharin cyclamates
  • acetosulfam sorbitol
  • sucralose xylitol
  • erythritol Stevia extract
  • L-aspartyl-L-phenyl-alanine ester e.g., aspartame
  • L-aspartyl-D-alanine alkyl amides L-aspartyl
  • Sweeteners may be present in a composition of the invention at a concentration range of about 2% to 20% by weight based on the total volume of the composition (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20%), though sweeteners may be present in lower or higher concentrations.
  • Exemplary flavoring agents include almond oil, amaretto oil, anethole, anise oil, benzaldehyde, blackberry, black walnut oil, blueberry, caraway, caraway oil, cardamom oil, cardamom seed, cherry juice, cherry syrup, cinnamon, cinnamon oil, cinnamon water, citric acid, citric acid syrup, clove oil, cocoa, coriander oil, dextrose, eriodictyon, ethyl acetate, ethyl vanillin, fennel oil, ginger, glucose, glycerin, glycyrrhiza, grape, honey, lavender oil, lemon oil, lime, mannitol, methyl salicylate, myristica oil, orange oil, orange peel, orange syrup, peppermint, peppermint oil, peppermint water, phenylethyl alcohol, pineapple, raspberry juice, raspberry syrup, rosemary oil, rose oil, rose water, sarsaparilla syrup, sorbitol, spearmint, spearmint oil
  • Coloring agents include, e.g., beta-carotene, riboflavin dyes, FD&C dyes (e.g., Yellow No. 5, Blue No. 1, Blue No. 2, and Red No. 40), FD&C lakes, chlorophylls and chlorophyllins, caramel coloring, annatto, cochineal, turmeric, saffron, paprika, and fruit, vegetable, and/or plant extracts (e.g., grape, black currant, aronia, carrot, beetroot, red cabbage, elderberry, and hibiscus extracts).
  • the amount of coloring agent used will vary depending on the agents used in the composition and the color intensity desired in the finished product. The amount of coloring agent to be used can be readily determined by one skilled in the art.
  • Non-limiting examples of vitamins and minerals that may be included in the compositions of the present invention include, e.g., choline bitartate, niacinamide, thiamin, folic acid, d-calcium pantothenate, biotin, vitamin A, vitamin C, vitamin B 1 hydrochloride, vitamin B 2 , vitamin B 3 , vitamin B 6 hydrochloride, vitamin B 12 , vitamin D, vitamin E acetate, vitamin K, and salts of calcium, potassium, magnesium, zinc, iodine, iron, and copper.
  • the composition contains at least 5, 10, 15, 20, 25, 30, 35, 40, 45, or 50% of the U.S. recommended daily intake (RDI) for such vitamins and minerals.
  • RDI U.S. recommended daily intake
  • preservatives may additionally be utilized in the compositions described herein.
  • exemplary preservatives include, for example, sorbate, benzoate, and polyphosphate preservatives (e.g., sorbic acid, benzoic acid, calcium sorbate, sodium sorbate, potassium sorbate, calcium benzoate, sodium benzoate, potassium benzoate, and mixtures thereof).
  • the preservative is included at levels from about 0.0005% to about 0.5% (e.g., 0.0005, 0.001, 0.005, 0.01, 0.05, 0.1, or 0.5%) by weight based on the total volume of the composition, though preservatives may be present in lower or higher concentrations.
  • antioxidant agents may also be included in the compositions to, for example, reduce exercise-induced oxidative stress.
  • exemplary antioxidants include vitamin C and vitamin E; beta-carotene, lutein, or other carotenoids; cyanidin, delphinidin, malvidin, or other anthocyanidins; apigenin, luteolin, or other flavones; hesperitin, naringenin, or other flavonones; isorhamnetin, quercetin, kaempferol or other flavonols; and epigallocatechin-3-gallate, epicatechin, thearubigins, or other flavan-3-ols.
  • compositions described herein may include amino acids (e.g., leucine, isoleucine, lysine, methionine, phenylalanine, threonine, tryptophan, and valine), stimulants (e.g., caffeine), emulsifying agents, carbon dioxide (e.g., to carbonate a liquid composition), stabilizers, humectants, anticaking agents, or herbal extracts.
  • amino acids e.g., leucine, isoleucine, lysine, methionine, phenylalanine, threonine, tryptophan, and valine
  • stimulants e.g., caffeine
  • emulsifying agents e.g., carbon dioxide (e.g., to carbonate a liquid composition)
  • carbon dioxide e.g., to carbonate a liquid composition
  • stabilizers e.g., to carbonate a liquid composition
  • humectants e.g., to carbon
  • additional therapeutic agent(s) may be administered with compositions of the present invention for, e.g., the treatment or amelioration of muscle cramps and/or the recovery of muscles from exercise fatigue.
  • therapeutic agents include, for example, muscle relaxants (e.g., diazepam) or anti-inflammatory agents (e.g., ibuprofen).
  • muscle relaxants e.g., diazepam
  • anti-inflammatory agents e.g., ibuprofen
  • the additional therapeutic agent(s) can be administered as a separate formulation or may be combined with any of the compositions described herein.
  • any of the compositions described herein can be used for the treatment of nocturnal (or night) cramps.
  • the compositions can be used in combination with one or more sleep aids.
  • Sleep aids that can be used in combination with the compositions and methods described herein include: antihistamines (e.g., diphenhydramine and doxylamine); benzodiazepines (e.g., estazolam (ProSom), flurazepam (Dalmane), quazepam (Doral), temazepam (Restoril), and triazolam (Halcion)); non-benzodiazepine sedative hypnotics (e.g., eszopiclone (Lunesta), zalepon (Sonata), and zolpidem (Ambien)); and melatonin receptor agonist hypnotics (e.g., ramelteon (Rozerem).
  • antihistamines e.g., diphenhydramine and
  • Still other sleep aids that can be used in combination with the compositions and methods described herein include: chamomile, valerian root, kava kava, lemon balm, passionflower, lavender, St. John's Wort, melatonin, tryptophan (e.g., L-tryptophan), 5-hydroxytryptophan (5-HTP), catnip, hops, rhodiola, oatstraw, lavender, GABA, L-theanine, linden, ginseng (e.g., Siberian ginseng), honey, nutmeg, mugwort, butterbur, rauwolfia, taumelloolch, American hellebore, quassia, tulip tree, brewer's yeast, inositol, skullcap, phosphatidylserine, calcium, magnesium, vitamin B6, vitamin B12, and pantothenic acid (B5).
  • tryptophan e.g., L-tryptophan
  • compositions and solutions of the present invention may be formulated as ready-to-drink beverages, concentrates (e.g., syrups), dry compositions (e.g., powders, granules, or tablets that may be reconstituted with a liquid (e.g., with water), gels, solids, semi-solids (e.g., ice cream, pudding, or yogurt), frozen liquids (e.g., ice pops), lozenges or hard candies, dissolving strips (e.g., an edible strip containing pullulan and compositions of the invention), and chewing gum.
  • concentrates e.g., syrups
  • dry compositions e.g., powders, granules, or tablets that may be reconstituted with a liquid (e.g., with water), gels, solids, semi-solids (e.g., ice cream, pudding, or yogurt), frozen liquids (e.g., ice pops), lozenges or hard candies, dissolving strips (e
  • the compositions may be in the form of a dry powder, granule, or tablet that may be reconstituted in a specified amount of a liquid.
  • the dried components may be mixed together and milled (e.g., to create a homogenous powder) or mixed in aqueous solution and dried by using methods known to one of skill in the art. Dried powders or granules may be “loose” or fashioned into tablets.
  • compositions described herein can be ingested, for example, by a subject before, during, or after exercise.
  • the compositions and solutions described herein can be ingested (e.g., through eating or drinking) before the onset of muscle cramping, when muscle cramping begins, any time after the onset of muscle cramping, or after muscle cramping has subsided.
  • the compositions of the solution can also be ingested after exercise to accelerate nerve-muscle recovery from exercise fatigue.
  • compositions and solutions of the present invention are in the form of a ready-to-drink beverage
  • a ready-to-drink beverage e.g., 1, 2, 4, 8, 10, 12, 14, 16, 18, 20, 24, 26, 28, 30, or 32 ounces of the beverage may be consumed as needed (e.g., once, twice, three, four, five, six times per day; once per week; or once per month).
  • compositions and solutions of the present invention may be prepared using methods known to one of skill in the art. Such methods include dissolving, dispersing, or otherwise mixing all components singularly or in suitable combinations and agitating with, for example, a mechanical stirrer until all of the ingredients have been solubilized or adequately dispersed. Where a shelf-stable composition or solution is desired, the final mixture can be pasteurized, ultra-pasteurized, sterilized, or filled aseptically at appropriate process conditions. Where required for mutual stability of two or more components (for example if a component is unstable at low pH), multiple components can be mixed shortly before ingestion.
  • compositions and solutions described herein may be bottled or packaged in, for example, glass bottles, plastic bottles and containers (e.g., polyethylene terephthalate or foil-lined ethylene vinyl alcohol), metal cans (e.g., coated aluminum or steel), lined cardboard containers, pouches, packs, wrappers, or any other packaging known to one of skill in the art.
  • a ready-to-drink beverage can be bottled or packaged in a unit that contains between 10-1000 mL of the beverage.
  • the packaging can contain 10, 20, 50, 100, 200, 300, 400, 500, 600, 700, 800, 900, or 1000 mL of the beverage.
  • the packaging can contain 200, 250, 330, 350, 355, 375, 440, or 500 mL of the beverage.
  • a ready-to-drink beverage can also be bottled or packaged in a unit that contains between 1-32 fluid ounces of beverage (e.g., the unit may contain 1, 2, 5, 6.75, 8, 8.3, 8.4, 8.45, 9.6, 10, 12, 15, 15.5, 16, 18.6, 20, 23, 24, or 32 fluid ounces).
  • the packaging is appropriately sterilized before being filled by the pasteurized, ultra-pasteurized, or sterilized composition or solution.
  • the packaging may feature multiple containers that can be mixed shortly before ingestion or that can be consumed serially.
  • TRP-Stim administered to the volunteers contained: a base of a 1:1 mixture of water and light karo syrup (for increased viscosity); 0.075% of a capsicum preparation intended for human use (Clearcap Super Soluble Caspsicum, Kalsec Inc.); 1% of a cinnamon volatile oil intended for human consumption (Aquaresin Cinnamon, Kalsec Inc); and 1.5% of a ginger oleoresin intended for human use (Aquaeresin Ginger, Kalsec Inc).
  • the active stimulation electrode was a 1.25′′ circular mesh-backed silver patch electrode (Reliamed) and was placed so as to produce contraction of the FHB with minimal stimulation amplitude.
  • the stimulation reference electrode was a 2′′ square patch electrode (Reliamed) placed on the opposite side of the foot. Cramping of the FHB was induced as described by Minetto et al. (ibid.) using a battery-powered electrical muscle stimulator (EMS-7500, Current Solutions LLC) to deliver pulses.
  • EMS-7500 battery-powered electrical muscle stimulator
  • a series of 180 microsecond biphasic square pulses of voltages were applied at various frequencies to stimulate the muscle.
  • the amplitude was adjusted to ⁇ 30% more than the threshold amplitude for eliciting strong contraction of the muscle.
  • the muscle was then stimulated by a train of 180 microsecond pulses of this amplitude delivered for 5 seconds at various frequencies.
  • the stimulation delivered by the stimulator also including “ramp up” and “ramp down” periods of 1 second preceding and following the main 5-sec stimulation period during which the amplitude of the pulses was ramped up or down to and from the final value.
  • Cramping was quantified by making EMG recordings from the belly of the FHB. Two external EMG recording electrodes (Vermed SilveRest) were placed along the belly of the FHB. The differential voltage relative to a third ground electrode placed at the ankle was amplified, digitized, and saved to computer using an I-330-C2+EMG unit with PhysiolLab software (J&J Engineering, Poulsbo, Wash.). The raw wide-band EMG signal (10-400 Hz) was processed by being rectified and integrated to provide the area under the curve (RMS). The duration of cramp was quantified by the time required for the RMS EMG to return to an amplitude of 3 standard deviations above the baseline value. This correlated well with duration of the cramp as observed by the return to the toe to resting position.
  • capsicum extract was applied to the neurons after being diluted in balanced salt solution (in mM: 145 NaCl, 5 KCl, 2 CaCl 2 , 1 MgCl 2 , 10 HEPES, and 10 glucose) which perfused the neurons.
  • Caspicum extract was applied at a dilution of 1/800,000, cinnamon extract at a dilution of 1/5,000, and ginger extract at a dilution of 1/12,000.
  • the calcium ionophore ionomycin was added following the tests with extracts to produce a large entry of calcium as an index of the maximal possible signal, illustrating the strength of activation by the heavily diluted extracts.
  • FIG. 1 shows graphs from six sensory neurons isolated from the trigeminal ganglia of rats, illustrating their activation by the capsicum, cinnamon, and ginger extracts that were used in the human experiments. Activation was quantified as an increase in intracellular free calcium, monitored by a fluorescent calcium indicator. Extracts were diluted into normal extracellular saline (Tyrode's solution) and were tested at lower concentrations than used in the beverage, taking account that concentrations present at nerve endings in mouth, esophagus, or stomach are expected to be lower than the beverage as a result of dilution into mucosa and interstitial fluid. All three extracts were capable of activating individual neurons when applied at concentrations 50-fold to 15.000-fold lower than used in the beverage.
  • Each trace shows a record from a different neuron, illustrating that some neurons could be activated by each of the extracts and that the strength of activation by each extract varied among particular neurons.
  • These records illustrate that each agent is capable of acting alone to activate some neurons and that a combination of agents can produce stronger activation of a larger fraction of neurons. Further, the bottom two records show that there can be strongly synergistic activation of neurons by the capsicum extract and the ginger extract when applied in combination.
  • Example 1 The in vitro data of Example 1 show that each individual component of the TRP-Stim solution by itself was capable of activating sensory neurons. Consistent with this, human experiments showed the efficacy of a beverage with capsicum alone (ClearCap capsicum at 1/2000 dilution) to inhibit cramping, achieved within 5 minutes.
  • FIGS. 2-8 show cramp relief by the administration of a uniform beverage composition designed for maximal TRP stimulation containing capsicum, cinnamon extract, and ginger extract, and where the physiological effects were monitored by EMG recording.
  • FIGS. 2-8 are graphs of EMG recordings of muscle contractions in seven human volunteers (four females and three males) that show the efficacy in preventing and treating cramps of ingesting 50 mL of a solution designed to stimulate TRPV1 and TRPA1 receptors in the mouth, esophagus, and stomach. Muscle cramps were induced by brief stimulation of toe or calf muscles ( FIGS. 2-7 ) or occurred spontaneously ( FIG. 8 ).
  • TRP-Stim solution containing capsaicin and capsaicinoids (TRPV1 agonists), cinnamaldehyde (TRPA1 agonist), and gingerols (TRPA1 and TRPV1 agonists).
  • TRPV1 agonists capsaicin and capsaicinoids
  • TRPA1 agonist cinnamaldehyde
  • TRPA1 and TRPV1 agonists were tested for muscle cramping using the same procedures as in control at times ranging from 4 minutes to 11 hours after ingestion.
  • FIG. 2 is a graph showing the effect of the TRP-Stim beverage on cramping of the flexor hallucis brevis of Subject A.
  • cramping was reliably induced by stimulating the muscle using an electrical muscle stimulator (EMS-7500, Current Solutions LLC) placed with external electrodes for FHB stimulation. Muscle activity was recorded using external electrodes placed over the belly of the muscle attached to an EMG amplifier (J&J Engineering I-330C2+).
  • EMG amplifier J&J Engineering I-330C2+
  • stimulation using 180 microsecond biphasic pulses delivered at 18 Hz for 5 seconds reliably and reproducibly produced cramping of the muscle, which was evident by EMG activity continuing after the cessation of stimulation.
  • cramping was very brief after 11 minutes and essentially absent at tests at 20 minutes and 21 ⁇ 2 hours after ingestion.
  • FIG. 3 is a graph showing the effect of the TRP-Stim beverage on cramping of the flexor hallucis brevis of a second subject.
  • cramping was induced by stimulation at 10 Hz for 5 seconds (180 microsecond pulses, amplitude set to ⁇ 30% higher than threshold for muscle contraction), and a longer cramp was induced by increasing the frequency to 12 Hz.
  • stimulation at 10 Hz or 12 Hz produced essentially no cramping, and increasing the frequency of stimulation to 14 Hz also did not induce cramping. The dramatic reduction in cramping was still present 4 hours later in this subject.
  • FIG. 4 is a graph showing the effect of the TRP-Stim beverage on cramping of the flexor hallucis brevis of a third subject tested over longer times.
  • a cramp lasting 58 seconds was induced by stimulation at 18 Hz for 5 seconds (180 microsecond pulses, amplitude set to ⁇ 30% higher than threshold for muscle contraction).
  • the duration of the cramp was reduced to 27 seconds after 8 minutes and to 8 seconds after 15 minutes.
  • Cramping was abolished after 20 minutes and in a test after 2 hours. In tests 11 hours after ingestion, reliable cramping had returned.
  • the subject again drank 50 mL of the TRP-Stim beverage, cramping was completely abolished in tests beginning after 10 minutes.
  • FIG. 5 is a graph showing the effect of the TRP-Stim beverage on cramping of the flexor hallucis brevis of a fourth subject.
  • This subject had engaged in strenuous exercise (triathlon) four hours earlier and was experiencing muscle twitchiness.
  • This subject had an unusually low frequency threshold (8 Hz) for induction of cramping in the FHB muscle, and the resulting cramps were unusually long (172 seconds after 8 Hz stimulation and 222 seconds after 10 Hz stimulation).
  • Cramping was completely gone in tests starting 13 minutes after ingestion of the TRP-Stim beverage, even when increasing the stimulation frequency to 12 Hz. Cramping was still abolished 3 hours later.
  • cramping returned with an increased frequency threshold (10 Hz) and shorter cramps than in control.
  • cramping was again completely abolished.
  • FIG. 6 is a graph showing the effect of the TRP-Stim beverage on cramping of the gastrocnemius (calf) muscle of a fifth subject.
  • the muscle was stimulated by a protocol ramping the frequency of stimulation from 2 Hz to 28 Hz (180 microsecond pulses, amplitude set to ⁇ 30% higher than threshold for muscle contraction). After cessation of stimulation, the muscle went into a prolonged cramp lasting 59 seconds. In a test 3 minutes after ingestion of 50 mL of TRP-Stim, cramping was abolished.
  • FIG. 7 is a graph showing the effect of the TRP-Stim beverage on cramping of the gastrocnemius (calf) muscle of a sixth subject.
  • the muscle was stimulated by a protocol ramping the frequency of stimulation from 2 Hz to 24 Hz (180 microsecond pulses, amplitude set to ⁇ 30% higher than threshold for muscle contraction). After cessation of stimulation, the muscle went into a prolonged cramp lasting 96 seconds. In a test 4 minutes after ingestion of 50 mL of TRP-Stim, cramping was abolished. Cramping was still abolished in a test conducted 40 minutes later.
  • FIG. 8 is a graph showing the effect of the TRP-Stim beverage on cramping of an FHB muscle in a seventh subject, who experienced spontaneous cramping induced by pointing her toe. In control conditions, voluntary toe flexes lasting ⁇ 5 seconds reliably produced cramping of the FHB lasting 5-8 seconds in different trials. Ten minutes after the subject ingested 50 mL of the TRP-Stim beverage, cramping was abolished.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Nutrition Science (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Physiology (AREA)
  • Pain & Pain Management (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
US13/191,941 2010-07-27 2011-07-27 Methods and compositions for preventing and relieving muscle cramps and for recovery from neuromuscular irritability and fatigue following exercise Abandoned US20120027693A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US13/191,941 US20120027693A1 (en) 2010-07-27 2011-07-27 Methods and compositions for preventing and relieving muscle cramps and for recovery from neuromuscular irritability and fatigue following exercise
US14/450,384 US9937135B2 (en) 2010-07-27 2014-08-04 Methods and compositions for preventing and relieving muscle cramps and for recovery from neuromuscular irritability and fatigue following exercise
US15/241,986 US10568853B2 (en) 2010-07-27 2016-08-19 Methods of treating muscle cramping and related compositions
US16/727,508 US20200375925A1 (en) 2010-07-27 2019-12-26 Methods of treating muscle cramping and related compositions
US17/571,884 US20220387539A1 (en) 2010-07-27 2022-01-10 Methods of treating muscle cramping and related compositions

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36805910P 2010-07-27 2010-07-27
US13/191,941 US20120027693A1 (en) 2010-07-27 2011-07-27 Methods and compositions for preventing and relieving muscle cramps and for recovery from neuromuscular irritability and fatigue following exercise

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US14/450,384 Continuation US9937135B2 (en) 2010-07-27 2014-08-04 Methods and compositions for preventing and relieving muscle cramps and for recovery from neuromuscular irritability and fatigue following exercise

Publications (1)

Publication Number Publication Date
US20120027693A1 true US20120027693A1 (en) 2012-02-02

Family

ID=45526958

Family Applications (5)

Application Number Title Priority Date Filing Date
US13/191,941 Abandoned US20120027693A1 (en) 2010-07-27 2011-07-27 Methods and compositions for preventing and relieving muscle cramps and for recovery from neuromuscular irritability and fatigue following exercise
US14/450,384 Active US9937135B2 (en) 2010-07-27 2014-08-04 Methods and compositions for preventing and relieving muscle cramps and for recovery from neuromuscular irritability and fatigue following exercise
US15/241,986 Active US10568853B2 (en) 2010-07-27 2016-08-19 Methods of treating muscle cramping and related compositions
US16/727,508 Abandoned US20200375925A1 (en) 2010-07-27 2019-12-26 Methods of treating muscle cramping and related compositions
US17/571,884 Pending US20220387539A1 (en) 2010-07-27 2022-01-10 Methods of treating muscle cramping and related compositions

Family Applications After (4)

Application Number Title Priority Date Filing Date
US14/450,384 Active US9937135B2 (en) 2010-07-27 2014-08-04 Methods and compositions for preventing and relieving muscle cramps and for recovery from neuromuscular irritability and fatigue following exercise
US15/241,986 Active US10568853B2 (en) 2010-07-27 2016-08-19 Methods of treating muscle cramping and related compositions
US16/727,508 Abandoned US20200375925A1 (en) 2010-07-27 2019-12-26 Methods of treating muscle cramping and related compositions
US17/571,884 Pending US20220387539A1 (en) 2010-07-27 2022-01-10 Methods of treating muscle cramping and related compositions

Country Status (11)

Country Link
US (5) US20120027693A1 (de)
EP (2) EP2629610B1 (de)
CY (1) CY1121824T1 (de)
DK (1) DK2629610T3 (de)
ES (1) ES2647087T3 (de)
HR (1) HRP20171744T1 (de)
HU (1) HUE035134T2 (de)
NO (1) NO2629610T3 (de)
PL (1) PL2629610T3 (de)
PT (1) PT2629610T (de)
WO (1) WO2012015882A1 (de)

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013028333A1 (en) * 2011-08-25 2013-02-28 Purebrands LLC Edible strips
GB2514417A (en) * 2013-05-24 2014-11-26 Susan Jane Branch Topical composition
US20150246066A1 (en) * 2014-02-28 2015-09-03 Daniel Nelson Nutritional supplement
WO2015160842A1 (en) * 2014-04-14 2015-10-22 Flex Pharma, Inc. Methods and formulatiions of capsaicinoids and capsinoids
WO2015160843A1 (en) * 2014-04-14 2015-10-22 Flex Pharma, Inc. Ion channel activators and methods of use
WO2016137478A1 (en) * 2015-02-26 2016-09-01 Koo Charles C Methods of and devices for chemical and threshold-gated electrical neuro-immuno-stimulation that triggers the stem cell growth to restore bodily functions
US20160263025A1 (en) * 2015-03-10 2016-09-15 CrampsAWAY Inc. Neuromuscular aid
WO2017062665A1 (en) * 2015-10-06 2017-04-13 Flex Pharma, Inc. Methods and compositions for unwanted or abnormal muscle contractions
US9713543B2 (en) 2011-02-16 2017-07-25 Charlie C. Koo Methods of and devices for chemical and threshold-gated electrical neuro-immuno-stimulation that triggers the stem cell growth to restore bodily functions
WO2017160156A1 (en) * 2016-03-18 2017-09-21 Axichem Ab Synthetic capasaicin analogs as trpv1 agonists
WO2018042330A1 (en) * 2016-08-30 2018-03-08 Omniactive Health Technologies Limited Improving physical performance with capsicum compositions
US20180069682A1 (en) * 2013-03-15 2018-03-08 Isco International, Llc Method and apparatus for signal interference processing
WO2018057954A1 (en) 2016-09-23 2018-03-29 Sentiens, Llc Agents and methods for modulating the sensory impact of tobacco or herbal smoke
US9937135B2 (en) 2010-07-27 2018-04-10 Flex Pharma, Inc. Methods and compositions for preventing and relieving muscle cramps and for recovery from neuromuscular irritability and fatigue following exercise
US20180360750A1 (en) * 2017-06-16 2018-12-20 Lillian Johnson Composition for reducing muscle cramps
US10159268B2 (en) 2013-02-08 2018-12-25 General Mills, Inc. Reduced sodium food products
EP3570861A4 (de) * 2017-01-23 2020-11-18 Flex Pharma, Inc. Zusammensetzungen und verfahren mit auswirkung auf die sportliche leistungsfähigkeit
US20210244061A1 (en) * 2018-05-09 2021-08-12 Domalina Pty Ltd ATF the Domalina Unit Trust A consumable gel delivery method for health ingredients
WO2024074839A1 (en) * 2022-10-07 2024-04-11 Nicoventures Trading Limited Oral product

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015231964A (ja) * 2014-06-09 2015-12-24 花王株式会社 運動神経活性化用皮膚塗布剤
US10898537B2 (en) 2015-07-31 2021-01-26 Delivra Inc. Transdermal formulations for delivery of capsaicinoids
CN107638473A (zh) * 2017-09-28 2018-01-30 苟稳 一种用于腓肠肌痉挛的中药药酒
US11730187B2 (en) 2019-05-08 2023-08-22 Gamot Global Pte. Ltd. Use of isothiocyanate in smokeless tobacco products
PL242445B1 (pl) * 2020-03-15 2023-02-20 Anwipharma Spolka Z Ograniczona Odpowiedzialnoscia Sposób otrzymywania preparatu i preparat zawierający elektrolity dla zwierząt kopytnych, zwłaszcza koni

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090215107A1 (en) * 2008-02-25 2009-08-27 Korea University, Anam-Dong Activator for Transient Receptor Potential Vanilloid 2 Comprising Probenecids

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4313958A (en) 1980-10-24 1982-02-02 The Procter & Gamble Company Method of producing analgesia
US4424205A (en) 1982-03-18 1984-01-03 The Procter & Gamble Company Hydroxyphenylacetamides having analgesic and anti-irritant activity
US4544669A (en) 1983-07-14 1985-10-01 The Procter & Gamble Company Compounds and compositions useful for producing analgesia
US4564633A (en) 1983-07-14 1986-01-14 The Procter & Gamble Company Compositions and methods useful for producing analgesia
US4532139A (en) 1983-07-14 1985-07-30 The Procter & Gamble Company Compounds and compositions useful for producing analgesia
US4493848A (en) 1983-07-14 1985-01-15 The Procter & Gamble Company Compositions and methods useful for producing analgesia
US4544668A (en) 1983-07-14 1985-10-01 The Procter & Gamble Company Compounds and compositions useful for producing analgesia
US4599342A (en) 1984-01-16 1986-07-08 The Procter & Gamble Company Pharmaceutical products providing enhanced analgesia
US4681897A (en) 1984-01-16 1987-07-21 The Procter & Gamble Company Pharmaceutical products providing enhanced analgesia
US4939149A (en) 1988-10-24 1990-07-03 The United States Of America As Represented By The Department Of Health And Human Services Resiniferatoxin and analogues thereof to cause sensory afferent C-fiber and thermoregulatory desensitization
US5403868A (en) 1988-12-23 1995-04-04 Sandoz Ltd. Capsaicin derivatives
US5221692A (en) 1991-08-22 1993-06-22 National Science Council Ether linked and relatively nonpungent analogues of N-nonanoyl vanillylamide
US5762963A (en) 1995-06-07 1998-06-09 Emory University Method and compositions for controlling oral and pharyngeal pain using capsaicinoids
CA2285203C (en) 1997-03-13 2005-07-26 James N. Campbell Compositions containing capsaicin or capsaicin analogues and a local anesthetic
JP4043605B2 (ja) 1998-07-02 2008-02-06 丸善製薬株式会社 カプサイシン類縁体の製造法
US6476076B1 (en) 1999-02-22 2002-11-05 Pacific Corporation Vanilloid analogues containing resinferatoxin pharmacophores as potent vanilloid receptor agonists and analgesics, compositions and uses thereof
US6534086B1 (en) * 2000-03-06 2003-03-18 Metagenics, Inc. Composition and method for treatment of inflammation and pain in mammals
US6274177B1 (en) 2000-08-26 2001-08-14 National Science Council Method of preparing an extract potent in anti-inflammation and anti-platelet aggregation from Zingiber officinale and pharmaceutical compositions containing said extract
US20030104085A1 (en) 2001-12-05 2003-06-05 Yeomans David C. Methods and compositions for treating back pain
US20030180226A1 (en) * 2002-01-23 2003-09-25 Haughton Pauline A. Anti-bacterial sneeze spray
WO2004092122A2 (en) 2003-04-08 2004-10-28 Algorx Pharmaceuticals, Inc. Preparation and purification of synthetic capsaicin
US20070020301A1 (en) * 2003-08-29 2007-01-25 Kao Corporation Beautification method
NO20034069L (no) 2003-09-12 2005-03-14 Aximed As Fremstilling og bruk av capsaicinderivater
ITMI20041566A1 (it) 2004-07-30 2004-10-30 Indena Spa "trpv1 agonisti, formulazioni che li contengono e loro usi"
FR2880625B1 (fr) 2005-01-07 2007-03-09 Sanofi Aventis Sa Derives de n-(heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique
BRPI0610333A2 (pt) 2005-04-25 2010-06-15 Neurogesx Inc compostos agonistas de trpv1 e métodos de fazer e usar os mesmos
CN101040720A (zh) * 2006-03-24 2007-09-26 沈华立 一种豆腐干的五香麻辣卤汤液
WO2008013861A2 (en) 2006-07-27 2008-01-31 Redpoint Bio Corporation Screening assay for inhibitors of trpa1 activation by a lower alkyl phenol
US8227603B2 (en) 2006-08-01 2012-07-24 Cytokinetics, Inc. Modulating skeletal muscle
EP2101819B1 (de) 2006-11-20 2013-01-09 President and Fellows of Harvard College Verfahren, zusammensetzungen und sets zur behandlung von schmerzen und pruritis
CN101889000B (zh) 2007-12-05 2012-11-28 詹森药业有限公司 二苯并氮杂*和二苯并氧氮杂*trpa1激动剂
EP2288922B1 (de) 2008-05-08 2016-08-17 University of Utah Research Foundation Sensorische rezeptoren für chronische müdigkeit und schmerzen und verwendungen dafür
NO2629610T3 (de) 2010-07-27 2018-02-03

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090215107A1 (en) * 2008-02-25 2009-08-27 Korea University, Anam-Dong Activator for Transient Receptor Potential Vanilloid 2 Comprising Probenecids

Cited By (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10568853B2 (en) 2010-07-27 2020-02-25 Cliff-Cartwright Corporation Methods of treating muscle cramping and related compositions
US9937135B2 (en) 2010-07-27 2018-04-10 Flex Pharma, Inc. Methods and compositions for preventing and relieving muscle cramps and for recovery from neuromuscular irritability and fatigue following exercise
US9713543B2 (en) 2011-02-16 2017-07-25 Charlie C. Koo Methods of and devices for chemical and threshold-gated electrical neuro-immuno-stimulation that triggers the stem cell growth to restore bodily functions
WO2013028333A1 (en) * 2011-08-25 2013-02-28 Purebrands LLC Edible strips
US11540539B2 (en) 2013-02-08 2023-01-03 General Mills, Inc. Reduced sodium food products
US10159268B2 (en) 2013-02-08 2018-12-25 General Mills, Inc. Reduced sodium food products
US20180069682A1 (en) * 2013-03-15 2018-03-08 Isco International, Llc Method and apparatus for signal interference processing
GB2514417A (en) * 2013-05-24 2014-11-26 Susan Jane Branch Topical composition
US20150246066A1 (en) * 2014-02-28 2015-09-03 Daniel Nelson Nutritional supplement
CN106232110A (zh) * 2014-04-14 2016-12-14 弗莱克斯制药股份有限公司 离子通道活化剂和使用方法
WO2015160842A1 (en) * 2014-04-14 2015-10-22 Flex Pharma, Inc. Methods and formulatiions of capsaicinoids and capsinoids
WO2015160843A1 (en) * 2014-04-14 2015-10-22 Flex Pharma, Inc. Ion channel activators and methods of use
US20190038573A1 (en) * 2014-04-14 2019-02-07 Flex Pharma, Inc. Ion channel activators and methods of use
JP2017513864A (ja) * 2014-04-14 2017-06-01 フレックス ファーマ， インコーポレイテッド イオンチャネル活性化剤及び使用方法
CN107396628A (zh) * 2015-02-26 2017-11-24 戈家霖 可诱使干细胞生长以修复身体机能的化学及阈值控制电神经免疫刺激：方法与器材
WO2016137478A1 (en) * 2015-02-26 2016-09-01 Koo Charles C Methods of and devices for chemical and threshold-gated electrical neuro-immuno-stimulation that triggers the stem cell growth to restore bodily functions
US20160263025A1 (en) * 2015-03-10 2016-09-15 CrampsAWAY Inc. Neuromuscular aid
US10034831B2 (en) * 2015-03-10 2018-07-31 CrampsAWAY Inc. Neuromuscular aid
US10493025B2 (en) 2015-03-10 2019-12-03 CrampsAWAY Inc. Neuromuscular aid
CN108367041A (zh) * 2015-10-06 2018-08-03 弗莱克斯制药股份有限公司 用于不希望的或异常的肌肉收缩的方法和组合物
WO2017062665A1 (en) * 2015-10-06 2017-04-13 Flex Pharma, Inc. Methods and compositions for unwanted or abnormal muscle contractions
WO2017160156A1 (en) * 2016-03-18 2017-09-21 Axichem Ab Synthetic capasaicin analogs as trpv1 agonists
US11382879B2 (en) 2016-08-30 2022-07-12 Omniactive Health Technologies Limited Methods for improving physical performance and capsicum compositions used therein
WO2018042330A1 (en) * 2016-08-30 2018-03-08 Omniactive Health Technologies Limited Improving physical performance with capsicum compositions
WO2018057954A1 (en) 2016-09-23 2018-03-29 Sentiens, Llc Agents and methods for modulating the sensory impact of tobacco or herbal smoke
EP3515215A4 (de) * 2016-09-23 2020-09-09 Sentiens, LLC Mittel und verfahren zur modulation der sensorischen auswirkung von tabak- oder pflanzlichem rauch
EP3570861A4 (de) * 2017-01-23 2020-11-18 Flex Pharma, Inc. Zusammensetzungen und verfahren mit auswirkung auf die sportliche leistungsfähigkeit
US11253493B2 (en) 2017-01-23 2022-02-22 Cliff-Cartwright Corporation Compositions and methods affecting exercise performance
US20180360750A1 (en) * 2017-06-16 2018-12-20 Lillian Johnson Composition for reducing muscle cramps
US20210244061A1 (en) * 2018-05-09 2021-08-12 Domalina Pty Ltd ATF the Domalina Unit Trust A consumable gel delivery method for health ingredients
WO2024074839A1 (en) * 2022-10-07 2024-04-11 Nicoventures Trading Limited Oral product

Also Published As

Publication number Publication date
US20200375925A1 (en) 2020-12-03
EP2629610B1 (de) 2017-09-06
US10568853B2 (en) 2020-02-25
PT2629610T (pt) 2017-11-24
ES2647087T3 (es) 2017-12-19
EP2629610A1 (de) 2013-08-28
US20140343156A1 (en) 2014-11-20
NO2629610T3 (de) 2018-02-03
CY1121824T1 (el) 2020-07-31
HRP20171744T1 (hr) 2018-01-12
US20160367506A1 (en) 2016-12-22
EP2629610A4 (de) 2014-08-06
HUE035134T2 (en) 2018-05-02
DK2629610T3 (da) 2017-11-20
US20220387539A1 (en) 2022-12-08
PL2629610T3 (pl) 2018-02-28
US9937135B2 (en) 2018-04-10
WO2012015882A1 (en) 2012-02-02
EP3295794A1 (de) 2018-03-21

Similar Documents

Publication Publication Date Title
US20220387539A1 (en) Methods of treating muscle cramping and related compositions
US20190038573A1 (en) Ion channel activators and methods of use
WO2015160842A1 (en) Methods and formulatiions of capsaicinoids and capsinoids
US6589555B2 (en) Effervescent vitaceutical compositions and related methods
ES2861583T3 (es) Preparación oral de acción rápida que puede aumentar el nivel de arginina en sangre y que comprende citrulina y arginina
BR112020006690A2 (pt) composições à base de plantas com biodisponibilidade aprimorada
BR112019010909A2 (pt) compostos medicinais e suplementos nutricionais à base de plantas de ação rápida
JP2021528420A (ja) 苦味のあるアミノ酸を含む治療及び健康のための組成物
JP6528800B2 (ja) アミノ酸組成物
KR20180058827A (ko) 원치 않는 또는 비정상적 근육 수축에 대한 방법 및 조성물
US20220401387A1 (en) Compositions and methods affecting exercise performance
JP2004175672A (ja) グリチルリチン酸含有経口用液剤
US20210177793A1 (en) INTERMITTENT ENDURANCE CAPACITY IMPROVING AGENT OR BLOOD pH ELEVATING AGENT
US20180333353A1 (en) Neuromuscular aid
RU2484842C2 (ru) Средство, обладающее общеукрепляющим, адаптогенным и препятствующим снижению иммунитета действием, и способ его получения
WO2020018911A1 (en) Nutritional compositions for enhancement of muscle performance
PL243659B1 (pl) Sucha kompozycja do rozpuszczania w wodzie

Legal Events

Date Code Title Description
AS Assignment

Owner name: FLEX PHARMA, INC., MASSACHUSETTS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BEAN, BRUCE;MACKINNON, DONALD;MACKINNON, RODERICK;SIGNING DATES FROM 20140312 TO 20140314;REEL/FRAME:032821/0238

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

AS Assignment

Owner name: CLIFF-CARTWRIGHT CORPORATION, MASSACHUSETTS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SALARIUS PHARMACEUTICALS, INC.;REEL/FRAME:050304/0192

Effective date: 20190723